cannabis

The agreement marks iX Biopharma’s official entry into the high-growth Australian cannabis market, which is expected to grow from US$0.04 billion in 2020 to US$1.23 billion in 2024.

SINGAPORE (Dec 5): iX Biopharma has been awarded a cannabis manufacture license from the Australian Office of Drug Control to manufacture and supply extracts and tinctures of cannabis and cannabis resins.

(June 8): Canada will legalise recreational cannabis on July 1.

SYDNEY (May 2): Tribeca Investment Partners Pty, owner of the world’s best-performing hedge fund last year, has found its next stock pick: a tiny grower of cannabis.

LONDON (March 24): There’s a buzz in Australia’s stock market. Shares of companies involved in the cultivation, production and research of medicinal marijuana have on average soared more than 130% in Sydney this year. That’s six times higher than th

SINGAPORE (March 16): In a country where cannabis – commonly also known as marijuana, weed or pot – is recognised as a Class A controlled drug, a bio-technology company is seeking to pursue opportunities in a sector where its medicinal use is legalise